image
Healthcare - Biotechnology - NASDAQ - US
$ 25.6
-0.389 %
$ 306 M
Market Cap
25.57
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one XOMAP stock under the worst case scenario is HIDDEN Compared to the current market price of 25.6 USD, XOMA Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one XOMAP stock under the base case scenario is HIDDEN Compared to the current market price of 25.6 USD, XOMA Corporation is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one XOMAP stock under the best case scenario is HIDDEN Compared to the current market price of 25.6 USD, XOMA Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart XOMAP

image
$26.4$26.4$26.2$26.2$26.0$26.0$25.8$25.8$25.6$25.6$25.4$25.4$25.2$25.2$25.0$25.0$24.8$24.8$24.6$24.6Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
28.5 M REVENUE
498.72%
-40 M OPERATING INCOME
4.47%
-13.8 M NET INCOME
66.15%
-13.7 M OPERATING CASH FLOW
24.29%
-28.3 M INVESTING CASH FLOW
-3874.54%
-11.1 M FINANCING CASH FLOW
-9.23%
15.9 M REVENUE
82.60%
5.93 M OPERATING INCOME
136.48%
2.37 M NET INCOME
159.65%
2.2 M OPERATING CASH FLOW
198.04%
-6.69 M INVESTING CASH FLOW
81.63%
-6.89 M FINANCING CASH FLOW
-546.72%
Balance Sheet XOMA Corporation
image
Current Assets 126 M
Cash & Short-Term Investments 105 M
Receivables 17 M
Other Current Assets 3.41 M
Non-Current Assets 95.7 M
Long-Term Investments 0
PP&E 351 K
Other Non-Current Assets 95.3 M
47.53 %7.69 %43.08 %Total Assets$221.3m
Current Liabilities 24.4 M
Accounts Payable 1.05 M
Short-Term Debt 12.3 M
Other Current Liabilities 11 M
Non-Current Liabilities 115 M
Long-Term Debt 107 M
Other Non-Current Liabilities 7.62 M
8.82 %7.92 %77.04 %5.47 %Total Liabilities$139.4m
EFFICIENCY
Earnings Waterfall XOMA Corporation
image
Revenue 28.5 M
Cost Of Revenue 206 K
Gross Profit 28.3 M
Operating Expenses 68.3 M
Operating Income -40 M
Other Expenses -26.2 M
Net Income -13.8 M
30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)28m(206k)28m(68m)(40m)26m(14m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
99.28% GROSS MARGIN
99.28%
-140.33% OPERATING MARGIN
-140.33%
-48.52% NET MARGIN
-48.52%
-16.87% ROE
-16.87%
-6.25% ROA
-6.25%
-13.62% ROIC
-13.62%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis XOMA Corporation
image
10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -13.8 M
Depreciation & Amortization 216 K
Capital Expenditures -20 K
Stock-Based Compensation 10.3 M
Change in Working Capital -2.79 M
Others -6.4 M
Free Cash Flow -13.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets XOMA Corporation
image
XOMAP has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.57% DIVIDEND YIELD
0.539 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
2.500002.500002.000002.000001.500001.500001.000001.000000.500000.500000.000000.000000.718750.539060.539060.539060.539060.539060.539060.539060.539060.539060.539060.539060.539060.539060.539060.539060.539062.340.539062.161.621.621.620.542021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership XOMA Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
8. Profile Summary

XOMA Corporation XOMAP

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 306 M
Dividend Yield 0.57%
Description XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Contact 2200 Powell Street, EmeryVille, CA, 94608 https://www.xoma.com
IPO Date Dec. 16, 2020
Employees 13
Officers Mr. Owen P. Hughes Jr. Chief Executive Officer & Director Mr. Bradley Sitko Chief Investment Officer Mr. Thomas M. Burns Senior Vice President of Finance & Chief Financial Officer